Sign In
Buy ENLV
$0.611
-0.0122 (-1.96%)
At Close: Jun 23, 2026
Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
08:05am, Thursday, 11'th Apr 2024
Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced posi
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
10:50am, Friday, 22'nd Mar 2024
ORLANDO, FL / ACCESSWIRE / March 22, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Unusual Machines Inc. (NYSE American:UMAC) on the RedChip Small Stock
NES-ZIONA, ISRAEL / ACCESSWIRE / February 26, 2024 / As we age, our knees start aching for reasons we can't quite pinpoint. Medicines temporarily decrease pain but don't help with the inflammatory chr
NES-ZIONA, ISRAEL / ACCESSWIRE / February 21, 2024 / Mike Williams made a name for himself making difficult endzone catches for the Tampa Bay Buccaneers. Around the corner from the stadium where he on
Nes-Ziona, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
08:00am, Wednesday, 20'th Dec 2023
Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis study Topline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 20, 2023 (GLOBE NE
New Strong Buy Stocks for November 3rd
09:02am, Friday, 03'rd Nov 2023
XRX, GVA, CUBI, LXU and ENLV have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2023.
New Strong Buy Stocks for October 27th
07:31am, Friday, 27'th Oct 2023
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
New Strong Buy Stocks for October 19th
08:16am, Thursday, 19'th Oct 2023
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
Enlivex to Present at the 2023 Jefferies Healthcare Conference
08:00am, Tuesday, 06'th Jun 2023
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
08:13am, Monday, 03'rd Oct 2022
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
02:08am, Friday, 30'th Sep 2022
Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholde
Enlivex to Present at the 2022 Jefferies Healthcare Conference
08:00am, Tuesday, 07'th Jun 2022
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patient
